source
- Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapiesBiogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the m…
- AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 millionAstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy. The agreement gives AstraZeneca full…